Cognetivity Unveils Groundbreaking Research on Cognition and Sleep – Extends Collaboration with University of Oxford

Cognetivity Neurosciences Unveils Groundbreaking Research on Cognition and Sleep – Extends Collaboration with University of Oxford

Company presents key data on measuring impact of sleep disorders on brain health; University of Oxford extends collaboration on monitoring changes in cognition of older adults

VANCOUVER, BC, March 23rd, 2023 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN) (OTCQB: CGNSF) (FWB: 1UB), a technology company that has created a unique brain health screening platform for use in medical, commercial and consumer environments, is pleased to announce important validation results for the use of its CognICA technology in measuring the impact of changes in sleep patterns on brain health, as well as further collaboration with Oxford University to detect the earliest signs of impairment associated with diseases such as Alzheimer’s.

Cognetivity’s Chief Innovation Officer, Dr Seyed-Mahdi Khaligh-Razavi will be presenting results on recent work on the impact of sleep on brain health at the 10th Congress of Asian Sleep Research (ASRS) on March 31st in Istanbul, Turkey. Normal sleep is essential for overall brain health and well-being, including cognition and memory formation. However, sleep disorders are highly prevalent and may affect 30-48% of older adults. To date, evaluating cognitive function, both subjectively and objectively, can be cumbersome and costly, but tracking cognitive performance in sleep disorders can help identify the appropriate frequency and duration of treatment, as well as optimize proposed lifestyle changes to meet individual needs.
At the conference Dr Khaligh-Razavi will present results showing the application of CognICA in tracking cognitive performance in relation to sleep. For patients with sleep disorders, the impact of treatment on their cognition, as measured quantitatively by Cognetivity’s CognICA technology, can be easily used to identify the optimal frequency and duration of treatment for each person. This then allows individuals to improve their brain health by improving their sleep patterns.
This can open up a huge market for Cognetivity, with the sleep technology devices market expected to grow from 15 billion in 2021 to over 67 billion in 2030, and growing interest in consumers in tracking sleep and measuring the impact on performance and health.
Cognetivity also announces the extension of its partnership with Oxford University on monitoring the cognition of individuals at risk of developing dementia. The purpose of the project is to detect the earliest signs of changes to allow the earliest possible intervention to preserve brain function and have the greatest positive impact of treatment. The study works with the Great Minds cohort, run by Dementia Platform UK, a business and research consortium which includes AstraZeneca, GSK, Janssen and Cognetivity as partners.

Cognetivity’s CEO Dr Sina Habibi commented “We are always delighted to share results from our ongoing R&D activities, especially when they open up markets as significant as managing sleep patterns, an area of growing concern for individuals and clinicians worldwide.” He added “When we add this to the expansion of our collaboration with such a fantastic academic partner as Oxford University, it shows our continued ability to deliver cutting edge research that demonstrates new use cases for our technology and its relevance and suitability for next-generation healthcare and consumer wellness.”

ON BEHALF OF THE BOARD

“Sina Habibi”
Sina Habibi

Chief Executive Officer and Director

FORWARD-LOOKING STATEMENTS:

Certain statements included in this news release  constitute  forward-looking  information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “assume” “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This news release contains forward looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present  and future business strategies and the environment in which the Company will operate in the future. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information: Please visit: www.cognetivity.com or contact: info@cognetivity.com; for media inquiries please contact pr@cognetivity.com